Latest research on Rituxan

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Rituxan indications

In the era of MabThera, the cure rate for DLBCL has increased significantly beyond that for the standard therapeutic strategy, but conventional treatment is still ineffective in approximately 30% of patients [1]; the reasons for this lack of activity in certain patients require investigation. [source, 2015]
In the era of MabThera, HBV infection has important effects on the prognosis of patients with DLBCL, and similar results have been previously reported [22–23]. [source, 2015]
Therefore, the use of MabThera increased the overall therapeutic effect in patients with DLBCL [1,7–8]. [source, 2015]
The successful stories of a novel indication of a drug for a new condition include Minoxidil, Viagra, Avastin, and Rituxan [3]. [source, 2015]
Significant data about the effects of rituximab in DLBCL patients was obtained from the results of the MabThera International Trail (MInT). [source, 2015]
However, another study showed that Rituxan plus CHOP had no curative effect.27 [source, 2015]
In the presence of contraindications, rituximab (MabThera) or, in certain cases, other cytotoxic and immunosuppressive drugs, such as Azathioprine, vincristine, Mycophenolate, or Cyclosporine, are administered [4, 6, 32]. [source, 2014]
Rituximab (Rituxan) is a chimeric (human/mouse) monoclonal antibody with IgG1 heavy-chain and kappa light chain constant region sequences and mouse variable region sequences, which depletes CD20+ B lymphocytes via cell-mediated and complement-dependent cytotoxic effects and promotes apoptosis of these cells [91]. [source, 2013]
This case emphasizes the need for an extensive tumor sampling and immunohistochemical analysis in atypical cases as our limited initial analysis would have rendered a diagnosis of a T cell/anaplastic PTLD, depriving the patient and clinician of potentially effective therapeutic modalities such as Rituxan. [source, 2013]
The similar effects of FcΓR polymorphisms on the anti-tumor effects of other cancer-reactive mAbs in clinical use (i.e., Rituxan, Trastuzumab, Cetuximab) suggest that patients with a favorable genotype may be selected for any mAb-based tumor therapy in which ADCC is a possible mechanism. [source, 2012]